Gabrielle Strobel writes a five-part series on the June 4 meeting of the Frontotemporal Degeneration Treatment Study Group (FTSG) held in Washington, DC.  “Scientists Strategize with Regulators for Frontal Assault on FTD” is the first part of the series.

Part 2: Toward FTD Therapeutic Trials: Diagnosis Firm, Outcomes Still Soft

Part 3: Case Studies Crystallize Trial Ideas at FTD Conference

Part 4: Take It From the Agency: First FTD Drug May Be an Orphan

Part 5: For FTD Drug Development, a Q&A With Regulators

Click here to read all five parts in one document.